● Live


You are here

Lupin advances on launching generic Tamiflu in US

  • Feb-12-2018
  • 14 Hrs IST

Lupin is currently trading at Rs. 843.00, up by 22.10 points or 2.69% from its previous closing of Rs. 820.90 on the BSE.

The scrip opened at Rs. 822.50 and has touched a high and low of Rs. 844.90 and Rs. 822.50 respectively. So far 92974 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 1510.00 on 10-Feb-2017 and a 52 week low of Rs. 782.10 on 07-Feb-2018.

Last one week high and low of the scrip stood at Rs. 859.50 and Rs. 782.10 respectively. The current market cap of the company is Rs. 38112.96 crore.

The promoters holding in the company stood at 47.02%, while Institutions and Non-Institutions held 37.64% and 15.35% respectively.

Lupin has launched Oseltamivir Phosphate Capsules, having received an approval from the United States Food and Drug Administration (USFDA) earlier. Oseltamivir Phosphate Capsules had annual sales of around $518 million in the US (IQVIA MAT December 2017).

Lupin’s Oseltamivir Phosphate Capsules, USP, 30 mg (base), 45 mg (base), and 75 mg (base) are the generic equivalent of Hoffman-La Roche, Inc.’s Tamiflu Capsules, 30 mg, 45 mg, and 75 mg. Oseltamivir Phosphate Capsules USP, 30 mg (base), 45 mg (base), and 75 mg (base) are indicated for the treatment of acute, uncomplicated influenza A and B in patients 2 weeks of age and older who have been symptomatic for no more than 48 hours, and prophylaxis of influenza A and B in patients 1 year and older.

Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally. The Company is a significant player in the Cardiovascular, Diabetology, Asthma, Pediatric, CNS, GI, Anti-Infective and NSAID space and holds global leadership position in the Anti-TB segment.